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Abstract
Aim The delivery of the Scottish Bowel Screening Pro-
gramme (SBoSP) is rooted in the provision of a high
quality, effective and participant-centred service. Safe and
effective colonoscopy forms an integral part of the pro-
cess. Additional accreditation as part of a multi-faceted
programme for participating colonoscopists, as in Eng-
land, does not exist in Scotland. This study aimed to
describe the quality of colonoscopy in the SBoSP and
compare this to the English national screening standards.
Methods Data were collected from the SBoSP between
2007 and 2014. End-points for analysis were caecal
intubation, cancer, polyp and adenoma detection, and
complications. Overall results were compared with 2012
published English national standards for screening and
outcomes from 2006 to 2009.
Results During the study period 53 332 participants
attended for colonoscopy. The colonoscopy completion
rate was 95.6% overall. The mean cancer detection rate
was 7.1%, the polyp detection rate was 45.7% and the
adenoma detection rate was 35.5%. The overall compli-
cation rate was 0.47%.
Conclusion Colonoscopy quality in the SBoSP has
exceeded the standard set for screening colonoscopy in
England, despite not adopting a multi-faceted pro-
gramme for screening colonoscopy. However, the over-
all adenoma detection rate in Scotland was 9.1% lower
than that in England which has implications for colono-
scopy quality and may have an impact on cancer preven-
tion rates, a key aim of the SBoSP.
Keywords Screening colonoscopy, performance
What does this paper add to the literature?
Our results demonstrate that, although high stan-
dards of colonoscopy can be delivered within a
national screening programme without the multi-
faceted approach adopted by the National Health
Service Bowel Cancer Screening Programme, the ade-
noma detection rate within the Scottish Bowel
Screening Programme is 9.1% less than the National
Health Service Bowel Cancer Screening Programme.
This is the first study to demonstrate this finding
and has important implications for the delivery of
screening colonoscopy.
Introduction
Population-based colorectal cancer (CRC) screening
using tests for the presence of occult blood in faeces
leads to a reduction in disease-specific mortality [1–3].
The primary aim of CRC screening is to reduce mortality
by early detection and treatment of cancer. A secondary
aim is to detect and remove adenomas in order to pre-
vent progression of these to cancer. The provision of
high quality colonoscopy within a screening programme
is fundamental to achieving these aims and has been
emphasized in recent studies and guidelines [4,5].
The adenoma detection rate (ADR) is a widely used
indicator of colonoscopy quality; it is a marker of both
the technical quality of the procedure and the efficacy
of the screening strategy [6,7]. ADR is known to vary
widely both between and within screening programmes
[8–11]. Much of this variation may be explained by fac-
tors relating to the quality of the colonoscopy
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performed. In a study of 300 000 screening, surveil-
lance or diagnostic colonoscopies, performed by 136
colonoscopists, the ADR was inversely associated with
the risks of interval CRC, advanced-stage interval cancer
and fatal interval cancer [12].
A UK audit of colonoscopy published in 2004 raised
concerns about the quality of colonoscopy in the UK,
showing caecal intubation in only 76.9% of 9223 proce-
dures and an overall perforation rate of 1:769 [13]. In
consequence, measures have been introduced in the UK
over the last decade to improve the quality of colonoscopy.
These include a national endoscopy training programme,
defined parameters for endoscopy training coordinated by
the Joint Advisory Group (JAG) on Gastrointestinal Endo-
scopy and national endoscopy standards (defined by the
Global Rating Score) [14]. In England, endoscopists wish-
ing to perform colonoscopy and centres wishing to partici-
pate in the National Health Service Bowel Cancer
Screening Programme (NHS BCSP) must undergo addi-
tional accreditation to ensure that investigation is under-
taken by a competent colonoscopist with appropriate
facilities and quality assurance. However, this process of
approving colonoscopists with a competency test was
deemed inappropriate in Scotland because of concerns
about introducing a two-tier colonoscopy service and, in
consequence, no such approval process exists. This study
aimed to assess whether, despite this, screening colono-
scopy quality in the Scottish Bowel Screening Programme
(SBoSP) is comparable to the English national standards
and published results from the NHS BCSP.
Method
All men and women aged between 50 and 74 years and
registered with a general practitioner were invited to
participate in the SBoSP. The SBoSP methodology has
been described previously [15] and is summarized here.
Each potential participant was then sent a pre-invitation
letter and guaiac faecal occult blood test (gFOBT) kit
(hema-screen, Immunostics Inc., Ocean, New Jersey,
USA, supplied by Alpha Laboratories Ltd, Eastleigh,
Hants, UK). Following any positive test result, individu-
als were pre-assessed, either face-to-face or through
telephone consultation, by a bowel screening specialist
endoscopy nurse and then referred for colonoscopy if
this was deemed appropriate. Bowel preparation was
performed in accordance with local guidelines, which
may vary between the hospital sites in Scotland at which
screening and other colonoscopies are performed.
In Scotland, screening colonoscopy was carried out
by colonoscopists selected by the 14 individual NHS
Boards responsible for delivery of healthcare. Clinical
standards developed by the SBoSP required that any
procedure should be performed by a colonoscopist who
had demonstrated at least 90% completion in continu-
ous audit and had undergone a JAG approved course in
basic skills in colonoscopy. However, specific individual
accreditation was not mandated – unlike in England
[16] where all screening colonoscopists are accredited
by means of a minimum number of lifetime procedures,
adequate performance data evident with continuous
audit, a knowledge test and a direct observation of the
performance of two procedures by two trained assessors
using a structured and validated competency framework
(DOPS, direct observation of procedural skills). In addi-
tion, unlike with the BCSP, in Scotland screening pro-
cedures are not necessarily performed on dedicated
screening lists and will depend on individual unit policy.
As such, results are self-reported.
The study population and associated dataset were
assembled by the Information Services Division of NHS
National Services Scotland. Data were extracted from
the Scottish Bowel Screening IT System. Colonoscopy
completion was defined as successful caecal intubation
on an intention to treat basis. Failed examinations
owing to, for example, obstructing lesions or poor
bowel preparation were counted as incomplete. Cancer,
polyp or adenoma detection was defined as the number
of participants examined who were found to have cancer
or polyps or adenomas respectively. Mean adenoma per
procedure was defined as the number of adenomas
detected divided by the total number of procedures.
Adverse events were defined as those that prevented
completion of the planned procedure (excluding techni-
cal failure or poor bowel preparation) or resulted in
admission to hospital, prolongation of existing hospital
stay, another interventional procedure or subsequent
medical consultation [16]. Adverse events were
recorded and validated by individual trusts. Results were
published and fed back to screening centres at trust
level. Missed cancers were defined as those diagnosed in
patients with a positive screening test and negative colo-
noscopy within a defined follow-up period, which was
2 years or the time between screening test result and
next round invitation, whichever occurs first.
To allow comparison with the NHS BCSP, which
commences screening at 60 years, a sub-group analysis
was performed for the 60–74-year-old population.
Statistical analysis
Continuous variables are presented as the mean (range).
Categorical variables are presented as a proportion (%).
Associations between categorical variables were exam-
ined using v2 tests for linear trend unless otherwise
specified. A P value of <0.05 was considered statistically
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significant. Statistical analysis was performed using SPSS
software (SPSS Inc., Chicago, Illinois, USA).
Results
From 2007 to 2014 inclusive, data from 5 308 336
invitations to participate in the SBoSP were available for
analysis: 2 954 199 (55.7%) successfully completed the
screening test and 68 140 (3.0%) gave positive screen-
ing test results. 53 332 participants (78.3%) who had
positive screening test results attended for colonoscopy.
31 102 participants (56.5%) attending colonoscopy
were men. The trend of examinations performed per
year is shown in Fig. 1. A total of 3777 cancers were
detected at colonoscopy with a positive predictive value
of colonoscopy (after a positive FOBT) for cancer of
7.1%. Polyps and adenomas were detected in 24 345
and 18 934 colonoscopies respectively.
Colonoscopy quality indicators
Colonoscopy completion rates were 95.6% overall,
96.9% in men and 93.7% in women. Caecal intubation
rates (CIR) deteriorated as the SBoSP was rolled out
nationally with the greatest deterioration observed in
women. CIR then gradually improved in both men and
women to a completion rate of 96.6% overall (Fig. 2).
The mean cancer detection rate (CDR) was 7.1%,
7.8% in men and 6.1% in women. The 60–74 year age
sub-group had an overall CDR of 8.4%, 9.3% in men
and 7.2% in women. The CDR dropped during the first
4 years of the SBoSP before reaching a plateau as can-
cers were ‘screened out’ of the population, representing
the overall shift from prevalence to incidence screening
(Fig. 3).
The mean polyp detection rate (PDR) was 45.7%,
52.0% in men and 36.8% in women. The 60–74 year
sub-group had an overall PDR of 47.0%, 53.0% in men
and 39.0% in women. The PDR increased during the
first 2 years of roll-out before reaching a plateau
(Fig. 4).
The mean ADR was 35.5%, 41.3% in men and 27.3%
in women (Table 1). Within the 60–74-year-old age
sub-group specifically, the ADR was 37.4% overall,
42.8% for men and 29.7% for women. The ADR since
national roll-out has remained consistent (Fig. 5). Simi-
lar to the situation observed with CIR during national
roll-out, the ADR reduced as additional hospitals and
endoscopists participated. This trend was observed in
both men and women. The mean number of adenomas
detected in those who had adenomas at colonoscopy
was 2.11.
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Figure 1 Number of colonoscopies performed per year in men
and women in the Scottish Bowel Screening Programme.
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Figure 2 Colonoscopy completion rates per year in men and
women as caecal intubation (%).
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Figure 3 Trends of cancer detection rates in men and women
in the Scottish Bowel Screening Programme.
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There were 269 complications overall (0.47%). Over-
all perforation rate was 0.08%. There were 11 pneu-
matic perforations, 14 mechanical perforations and 20
therapeutic perforations. Post-colonoscopy bleeding
requiring admission occurred in 213 participants
(0.37%). There were 11 sedation-related complications
(0.02%). There was one colonoscopy-related mortality.
Data for missed cancers are available for 2007–2009.
There were 12 cases of missed cancer within this group
(0.17).
A comparison between the main outcomes in the
SBoCP (2007–2014) and the NHS BCSP (2006–2009)
is given in Table 2. The outstanding difference is the
ADR: 37.4% in Scotland (60–74 year age group) and
46.5% in England. Unpublished data from the BCSP to
2014 have shown a continuous improvement in
adjusted ADR to 47.4%. Comparable study period
BSCP data for complication rates and missed cancer
rates are not available.
Discussion
This study demonstrates high-quality colonoscopy in
the SBoSP. The data show that colonoscopy can be
delivered to a high standard, thus ensuring screening
participant safety. The results compare very favourably
with the 2004 English national audit in which the
unadjusted CIR was 76.9% [13] and are similar to the
2011 national audit (95.6% vs 92.3%) [17] and 2012
NHS BCSP reported quality measures (95.6% vs 95.2%)
[7].
Colonoscopy in general needs to strike a balance
between risks and benefits. Within the context of any
bowel screening programme, this balance is exagger-
ated, because asymptomatic participants, not patients
with symptoms, are placed in harm’s way. The proce-
dure is invasive, with the potential for causing serious
and significant adverse events [18]. Colonoscopy perfor-
mance has been found in the past to be variable, as
demonstrated by a national audit that demonstrated
poor completion rates and higher than expected perfo-
ration rates [13]. Strategies to attain and maintain mini-
mum standards through quality assurance frameworks
were introduced in England to ensure equity of provi-
sion and access to consistent reproducible standards for
screening participants throughout the NHS BCSP, aim-
ing to minimize the risks and maximize the benefits of
screening. This quality assurance framework is sup-
ported through the JAG accreditation of endoscopy
units and through rigorous accreditation for
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Figure 4 Trends of polyp detection rates in men and women
in the Scottish Bowel Screening Programme.
Table 1 Colonoscopy key performance indicators.
n Complete (%) Cancer CDR
CDR
(60–74
years) Polyp PDR
PDR
(60–74
years)* Adenoma ADR
ADR
(60–74
years)
Men 31 102 30 143 (96.9) 3011 0.10 0.09 16 174 0.52 0.53 12 865 0.41 0.43
Women 22 230 20 824 (93.7) 1639 0.07 0.07 8171 0.37 0.39 6069 0.27 0.27
Total 53 332 50 967 (95.6) 4650 0.09 0.08 24 345 0.46 0.47 18 934 0.36 0.37
CDR, cancer detection rate; PDR, polyp detection rate; ADR, adenoma detection rate.
*Sub-group analysis of participants aged 60–74 years.
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Figure 5 Trends of adenoma detection rates in men and
women in the Scottish Bowel Screening Programme.
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colonoscopists participating in the NHS BCSP. Failure
by an accredited BCSP colonoscopist to reach agreed
standards, or to provide the required data returns, may
result in a series of sanctions [16].
The SBoSP CDR was lower than that advocated in
the quality assurance guidelines [16]. However, Scottish
results are comparable to those published from the first
million invitations in England [19]. In addition, the
publication on colonoscopy quality measures within the
NHS BCSP argued against, and omitted, the CDR as a
quality measure. The data on trends of cancer detection
as part of a national programme demonstrate lower
CDR in subsequent incident rounds compared with the
prevalent round [20], consistent with other bowel
screening programmes [20,21]. As such, the CDR rep-
resents a poor marker of screening colonoscopy quality
and reflects cancer incidence more [11,22].
Polyp detection rates are independently a poor indi-
cator of colonoscopy performance and are omitted from
many programmes as a quality indicator. As such com-
paring the PDR of different programmes is difficult due
to inconsistent reporting. However, with careful audit
or PDR to ADR ratio, it is recognized that the PDR
can be used as a surrogate for ADR [23].
However, the most widely used metric for assessing
colonoscopy quality is the ADR. Our study showed a
mean ADR of 35.5%, reflecting the above average risk of
detecting adenomas in people with a positive screening
test result in the target age group. The lower ADR in
Scotland compared with England (35.6% vs 46.5%) is not
a result of the lower age of the beginning of invitations to
screen compared with England (50 vs 60 years). The ADR
reported here is similar to the pilot evaluation of bowel
cancer screening in the UK which had an inclusion age
range of 50–70 years [11,22]. However, when a sub-
group analysis is performed during a similar time period
when prevalence screening would be similar to participants
aged 60–74 years, the unadjusted ADR in Scotland
remains 9.1% lower than that achieved in England.
Unpublished data provided by the BCSP have
demonstrated that, within the BSCP, the adjusted ADR
has continued to increase and was 47.4% in 2014.
While this could be explained by regional differences in
adenoma prevalence, this seems unlikely given the over-
all higher levels of deprivation and higher incidence of
CRC in Scotland than in England [24]. This difference
is clinically significant given the known association
between ADR and interval cancer rate. In a US study
which analysed post-colonoscopy cancer development
rates for individual endoscopists, a 1% increase in ADR
was associated with a 3% reduction in subsequent cancer
development rates. Whilst this calculation cannot be
applied to any bowel cancer screening programme, it
does highlight the importance of improving standards
and increasing the ADR. The reasons may be multi-fac-
torial and require further investigation. However, the
design and set-up of the two programmes must be a
contributing factor. Different to the SBoSP, with the
BCSP there was selection (commissioning) of both
screening centres and screening colonoscopists, using
accreditation as the criterion. These processes were
intended (a) to give the programme the best chance of
success from the outset and (b) to continually drive up
standards once the programme started. A number of
factors unique to the BCSP encourage continuous qual-
ity improvement. Patients in the BCSP have their proce-
dure done on a dedicated list, adjusted for the case mix,
giving extra time to perform a screening colonoscopy,
with a maximum of four cases per list. There is also a
regular review of screening centres by BCSP and JAG
quality assurance teams and continuous feedback of
ADR and other quality parameters to screening centres
and individuals. In addition within the BCSP there are
defined processes for mentoring screeners and dealing
with poor performance with further training or, if stan-
dards are still not met, retirement from the programme.
Even the threat of being reviewed is likely to have an
effect. Of course it is not possible to say which of these
Table 2 Scottish Bowel Screening Programme (SBoSP) quality indicators for the 60–74-year-old sub-group compared with the
English NHS Bowel Cancer Screening Programme (BCSP) reported results, quality assurance guidelines and target standards.
Guidelines
(%)
Target
(%)
SBoSP
(%)
NHS BCSP
(%) [7] P
Caecal intubation 90 >97 95.2 95.2 ns
Cancer detection 11 8.0 10.6 <0.001
Adenoma detection 35 40 37.4 46.5 <0.001
Perforation <0.1 0.08 0.09 ns
Polypectomy perforation <0.5 0.08
Bleeding <1.0 0.37
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processes had the greatest impact but evidence indicates
that high quality and continuous improvement is more
likely when several things are done simultaneously and
may explain the reason why there has been no change
in ADR over time within the SBoSP [25].
The adverse event rates in this study are similar to
other published series, which typically report post-colo-
noscopy bleeding in 0.03%–0.22% of procedures and
perforation in 0.01%–0.80% of procedures. Accepting
that 35.5% of procedures require at least one polypec-
tomy and many involve removal of large and multiple
polyps, the low level of adverse events is pleasing and
compares favourably to those of the 2004 (0.50%) [13]
and 2011 audits [17]. However, it must be noted that
a direct comparison with the BCSP is flawed due to the
different methodologies of reporting.
The complete collection and quality of the data is a
major strength of this study. Quality of collected data is
itself a marker of quality of a screening programme and
feedback on data quality issues raised through this study
will improve the future quality of the data collection
process. An important additional strength of this study
is its size, both in terms of the number of colonoscopies
analysed and the nationwide coverage of the SBoSP.
These data show that a high level of colonoscopy quality
can be achieved in a large screening programme. Never-
theless, our study has several limitations. FOBT-based
national screening programmes are now uncommon
across the world so that comparison of colonoscopy qual-
ity with other countries is difficult. In addition, data for
individual colonoscopists, sedation practices and patient
comfort satisfaction scores are not collected routinely. It
is widely accepted that the reporting of sedation practice
provides a surrogate marker for technical quality, partici-
pant safety and participant experience and reflects overall
colonoscopy quality as part of a screening programme
[16,26].
The results presented here demonstrate that colono-
scopic quality in the SBoSP is acceptable according to
the standards set by the NHS BCSP quality assurance
guidelines in England. The Scottish programme without
accreditation delivers a high quality screening process
with quality markers exceeding those set initially in
other programmes. However, the published data from
the English programme do demonstrate higher ADRs.
The accreditation process may be one of many impor-
tant factors in this. In consequence, our study therefore
vindicates the decision by the English NHS BSCP to
adopt a multi-faceted approach to ensuring high quality
colonoscopy, a component of which is the accreditation
test for screening colonoscopists. It also highlights the
potential for improvement of colonoscopy quality
within the SBoSP and supports measures to drive for-
ward standards within the programme.
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Commentary: Accrediting colonoscopy services and
colonoscopists for screening makes a difference
The report from Quyn et al. [1] in this issue describes
the performance of the Scottish Bowel Cancer Screen-
ing Programme and makes comparisons with the Eng-
lish Bowel Cancer Screening Programme (BCSP). The
processes of invitation and selection for colonoscopy in
the two programmes are identical, but with different
age ranges. However, there are differences in the prepa-
ration, delivery and monitoring of colonoscopy services
to investigate screen detected positives. A comparison
of colonoscopy performance enables inferences as to
whether different approaches are significant.
The main finding is of a substantial difference (9%) in
the adenoma detection rates (ADR) in the 60–74 age
cohorts. There was no statistical test of difference but the
sample size is large and the difference is likely to be statisti-
cally significant. Are the differences clinically significant?
Three studies have shown that low ADR is associated with
higher rates of interval cancer [2–4]. In one of these, it was
estimated that for every 1% increase in ADR there is a 3%
reduction in risk of colorectal cancer [3]. This estimate was
based on a study of colonoscopy in an average risk screen-
ing population in the west coast of America and may not
be applicable in the UK setting. However, most colono-
scopists would consider a 9% difference in ADR to be
clinically important. The available literature suggests that
we shall see higher rates of post colonoscopy colorectal
cancer [5] in patients who have had a colonoscopy in the
Scottish programme.
How did this difference arise and what lessons can
we learn? Given a similar ethnic mix and higher levels
of social deprivation, smoking and drinking in the
Scottish population compared to England, it seems
improbable that lower ADR was due to biological or
lifestyle differences in the screened populations. Per-
haps, the most likely explanation is the different
approach preparing, delivering and monitoring colono-
scopy services.
The key differences in approach are in England:
designated, JAG accredited [6], colonoscopy screening
centres; screening colonoscopists who undergo a sum-
mative test of competence [7]; and dedicated lists for
screening colonoscopy with a maximum of four
patients on a list. Furthermore, in England all screen-
ing centres and colonoscopists receive individual level
colonoscopy performance data regularly and there was
a defined process to identify and support poor per-
formers [8]. The Scottish programme did not do any
of these things, or at least not to the same degree.
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